GET DAILY SIGNALSLiquidia (LQDA) Eyes +243% Revenue Jump in Q3 2026 Earnings
Key Takeaways
- Liquidia Corporation (LQDA) is scheduled to release its third quarter 2026 financial results on Monday, November 9, 2026, before the market opens.
- Consensus estimates point to earnings of about $0.77 per share, marking a notable turnaround from the $0.04 loss in the same quarter last year.
- Preliminary third quarter Yutrepia sales of roughly $222.7 million, shared in October, topped analyst forecasts of around $201.5 million.
- The company has exceeded consensus EPS estimates in each of the past four quarters.
- A $380.7 million settlement with United Therapeutics, stemming from a September 2026 court decision, stands out as an important cost factor to monitor.
Why This Earnings Report Matters
Liquidia focuses on treatments for respiratory and vascular conditions, with its commercial path now closely tied to Yutrepia, an inhaled treprostinil therapy for pulmonary arterial hypertension and related conditions. The upcoming third quarter update offers a key look at how the drug's launch is progressing after strong year-over-year revenue gains in prior periods. I am watching closely to see if Yutrepia's momentum holds, how the settlement payment affects results, and whether management sticks with its target of more than $1 billion in net revenue by 2027. These numbers come at a time of active estimate revisions and stock price swings.
Earnings Expectations
Analysts project earnings of $0.77 per share and revenue near $186.63 million for the third quarter, implying roughly 243% year-over-year revenue growth from $54.34 million in the prior-year period. Other estimates place EPS in a narrow range around $0.77 to $0.79, with revenue figures varying somewhat. This follows a second quarter where Liquidia posted revenue of $171.68 million and EPS of $0.74, just missing the $0.76 consensus while beating on the top line. Attention will center on Yutrepia net sales, margins, operating costs, and any guidance updates. The preliminary $222.7 million in Yutrepia sales already surpassed the $201.5 million expectation, hinting that revenue could exceed earlier projections. Settlement charges and R&D spending will also draw scrutiny for their impact on earnings.
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Investor sentiment ahead of the report stays measured even with the solid commercial progress. The stock has experienced notable swings after earnings, including a negative drift following the August 2026 release, and shares have traded in the mid-$20s after pulling back from higher levels. Analyst price targets have moved in different directions, with Needham cutting its target to $58 while keeping a Buy rating and HC Wainwright adjusting EPS forecasts downward several times. Short interest near 20% of the float as of mid-October reflects ongoing questions about valuation and risks, even as preliminary sales came in ahead of expectations.
Forward Outlook and Key Factors to Monitor
Looking past the headline numbers, several items deserve attention in coming quarters. The $380.7 million settlement will be paid in stages through 2026 and 2027, which could lead to uneven quarterly results despite improving commercial trends. Yutrepia prescription growth and net pricing will drive the story, and management has kept its $1 billion-plus net revenue goal for 2027 in focus. Gross margins above 90% will be watched for consistency as the launch continues. Additional pipeline updates, competitive developments, and R&D spending levels also matter. With cash at about $396 million as of September 30, 2026, the balance sheet offers some flexibility, though settlement payments and commercialization expenses will influence how it is used. Clarity on guidance and cost management will help assess whether top-line strength leads to sustained profitability.
Exploring AI Tools for Stock Analysis
From what I see, Tickeron’s AI Screener has become a helpful part of my routine when evaluating names like this one. It lets me apply filters for technical patterns, fundamentals, and industry trends to surface ideas quickly. I find it useful for spotting comparable opportunities without spending hours on manual checks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LQDA's RSI Indicator recovers from oversold territory
The RSI Oscillator for LQDA moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LQDA as a result. In 71 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for LQDA just turned positive on October 16, 2026. Looking at past instances where LQDA's MACD turned positive, the stock continued to rise in 47 of 53 cases over the following month. The odds of a continued upward trend are 89%.
Following a +4.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where LQDA advanced for three days, in 282 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
LQDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for LQDA moved below the 200-day moving average on October 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LQDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. LQDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.199) is normal, around the industry mean (8.029). P/E Ratio (26.487) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (14.286) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of particle-based vaccines and therapeutics for prevention and treatment of human disease
Industry PharmaceuticalsGeneric
Advertisement